Holen Sie sich die Stockscreener-App
46.23
0.00%
0.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$46.20
Offen:
$46.32
24-Stunden-Volumen:
2.23M
Relative Volume:
0.18
Marktkapitalisierung:
$94.14B
Einnahmen:
$47.70B
Nettoeinkommen (Verlust:
$5.07B
KGV:
18.64
EPS:
2.48
Netto-Cashflow:
$14.58B
1W Leistung:
-1.11%
1M Leistung:
-4.62%
6M Leistung:
-21.71%
1J Leistung:
-5.96%
1-Tages-Spanne:
$46.09
$46.73
1-Wochen-Bereich:
$46.09
$48.19
52-Wochen-Spanne:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.25 | 94.04B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
750.12 | 677.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.86 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
215.54 | 385.71B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.54 | 240.28B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.78 | 206.84B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb: Hold Rating Amid Slower Cobenfy Launch and Fair Valuation - TipRanks
Aug Wrap: Will Bristol Myers Squibb Company Equity Right stock hit new highs in YEARWall Street Watch & AI Enhanced Trade Execution Alerts - خودرو بانک
Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC - insights.citeline.com
Ascent Group LLC Buys 8,721 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Promising Lung Cancer Trial Results Could Be a Game Changer for Bristol-Myers Squibb (BMY) - simplywall.st
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $1.38 Billion Position in Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% - MSN
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? - Yahoo Finance
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stance Capital LLC Purchases 39,165 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Graham Capital Management L.P. Invests $568,000 in Bristol Myers Squibb Company $BMY - MarketBeat
BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer - Insider Monkey
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
October 31st Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? - Yahoo Finance
Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Acquired by Bayforest Capital Ltd - MarketBeat
United Services Automobile Association Has $12.60 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know - Yahoo Finance
BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy - MSN
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
BioNTech and Bristol Myers Squibb amend partnership for BNT327 with $1.5 billion upfront payment - Investing.com Canada
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - The Manila Times
BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial - TipRanks
BioNTech and Bristol Myers Squibb Announce Encouraging Phase 2 Data for Pumitamig Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer - Quiver Quantitative
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose - Fierce Biotech
Bristol-Myers Squibb at Morgan Stanley Conference: Strategic Insights - Investing.com
Hold Recommendation for Bristol-Myers Squibb Due to Cobenfy’s Modest Growth and Revenue Projections - TipRanks
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Purchased by Baird Financial Group Inc. - MarketBeat
What is Bristol Myers Squibb Company s debt to equity ratioWeekly Earnings Recap & Free Accurate Trade Setup Notifications - خودرو بانک
Is Bristol-Myers Squibb (BMY) a Value Trap or a Sleeping Giant in Biopharma? - AInvest
Short interest data insights for Bristol Myers Squibb Company Equity RightJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Using data tools to time your Bristol Myers Squibb Company exitGap Down & Fast Entry and Exit Trade Plans - Newser
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug - BioPharma Dive
Independent research - Bristol Myers Squibb
Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing Appeal - Law360
Top chart patterns to watch in Bristol Myers Squibb CompanyMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
J&J, Bristol Myers Lose Bid to Revive Suit Over Drug Price Talks - Bloomberg Law News
How Is Bristol-Myers’ Stock Performance Compared To Other Pharma Stocks? - Barchart.com
Mubadala Investment Co PJSC Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Not As Cheap As It Might Seem (NYSE:BMY) - Seeking Alpha
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Yahoo Finance
Combining machine learning predictions for Bristol Myers Squibb CompanyPortfolio Update Report & Expert Curated Trade Ideas - Newser
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):